Table 2 |
||||
|
Clinical symptoms of mixed connective tissue disease patients with and without cardiovascular diseases |
||||
|
MCTD manifestation |
MCTD (n = 50) |
MCTD/CVD+ (n = 23) |
MCTD/CVD- (n = 27) |
P valuea, CVD+ vs. CVD- |
|
|
||||
|
Disease duration (years) |
9.56 ± 6.8 (3 to 26) |
10.3 ± 6.6 (3 to 26) |
8.9 ± 6.9 (3 to 25) |
0.481 |
|
Polyarthritis |
46 (92) |
22 (95.6) |
24 (88.8) |
0.6123 |
|
Raynaud's phenomenon |
39 (78) |
22 (95.6) |
17 (62.9) |
0.006 |
|
Myositis |
30 (60) |
13 (56.5) |
17 (62.9) |
0.8621 |
|
Interstitial lung disease |
40 (80) |
19 (82.6) |
21 (77.7) |
0.7356 |
|
Photosensitivity |
12 (24) |
7 (30.4) |
5 (18.5) |
0.5077 |
|
Esophageal dysmotility |
35 (70) |
15 (65.2) |
20 (74.0) |
0.5480 |
|
Pulmonary arterial hypertension |
12 (24) |
9 (39.1) |
3 (11.1) |
0.0141 |
|
Lymphadenomegaly |
13 (0.26) |
5 (21.7) |
8 (29.6) |
0.7474 |
|
Serositis |
19 (38) |
11 (47.8) |
8 (29.6) |
0.2465 |
|
Secondary antiphospholipid syndrome |
15 (30) |
11 (47.8) |
4 (14.8) |
0.015 |
|
Previous venous thrombosis |
13 (26.0) |
9 (39.1) |
4 (14.8) |
0.618 |
|
Previous arterial occlusion |
2 (4.0) |
2 (8.69) |
0 |
|
|
Anti-U1RNP (normal: <10 U/ml) |
50 (100) |
23 (100) |
27 (100) |
|
|
Anti-CL IgG/IgM (normal: <10 U/ml) |
19 (38) |
13 (56) |
6 (22) |
0.0195 |
|
AECA (normal: <5 U/ml) |
22 (44) |
15 (65) |
7 (26) |
0.001 |
|
SLAM (median) |
5 |
5 |
4 |
|
|
SLAM (mean ± SD) |
6.28 ± 4.04 |
6.95 ± 4.08 |
5.44 ± 4.0 |
0.199 |
|
SLAM (n) |
18 (36) |
11 (47.8) |
7 (25.9) |
0.1438 |
|
Medication |
||||
|
Nonsteroidal anti-inflammatory drugs |
22 (44) |
10 (43.4) |
12 (44.4) |
1.0 |
|
Last 2 months average dose of corticosteroids (mg/day) |
3.36 ± 4.8 |
4.1 ± 3.4 |
3.1 ± 5.2 |
0.5306 |
|
Cumulative lifetime dose (prednisone equivalent) |
14.21 (4 to 58.965) |
13.0 (4 to 59.432) |
15.2 (4 to 57.437) |
0.674 |
|
Corticosteroids alone or combination (n) |
28 (56) |
11 (47.8) |
17 (62.9) |
0.3926 |
|
Patients currently corticosteroids alone n (%) |
7 (14) |
2 (8.6) |
5 (18.5) |
0.4295 |
|
Patients currently corticosteroids plus salazopyrine |
10 (20) |
5 (21.7) |
5 (18.5) |
1.0 |
|
Patients currently corticosteroids plus methotrexate |
11 (22) |
5 (21.7) |
6 (22.2) |
1.00 |
|
Cyclophosphamide treatment ever |
37 (74) |
21 (91.3) |
16 (59.2) |
0.0119 |
|
Antimalaric drugs treatment ever |
39 (78) |
19 (82.6) |
20 (74.0) |
0.515 |
|
Cyclosporin-A treatment ever |
10 (20) |
7 (30.4) |
3 (11.1) |
0.4804 |
|
|
||||
|
Data presented as mean ± standard deviation, n (%) or median (25th to 75th percentile). AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; CVD, cardiovascular disease; MCTD, mixed connective tissue disease. The systemic lupus erythematosus disease activity measure (SLAM) is a measure of disease activity [24,25]. aFischer's exact test and Student t test. |
||||
|
Soltesz et al. Arthritis Research & Therapy 2010 12:R78 doi:10.1186/ar2999 |
||||
